Beam Therapeutics reported a quarterly loss of $0.91 per share, wider than the Zacks Consensus Estimate for a $0.87 loss. The loss was still an improvement from a $1.24 loss per share a year ago, indicating year-over-year progress despite the modest earnings miss. The update is notable for BEAM but is unlikely to have broad market impact.
Beam Therapeutics reported a quarterly loss of $0.91 per share, wider than the Zacks Consensus Estimate for a $0.87 loss. The loss was still an improvement from a $1.24 loss per share a year ago, indicating year-over-year progress despite the modest earnings miss. The update is notable for BEAM but is unlikely to have broad market impact.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly negative
Sentiment Score
-0.15
Ticker Sentiment
